Cerinib Capsule 150 mg contains Ceritinib, a targeted cancer therapy classified as an ALK (anaplastic lymphoma kinase) inhibitor. Ceritinib works by blocking the activity of the ALK protein, which is abnormally active in certain types of cancer cells, particularly in non-small cell lung cancer (NSCLC). By inhibiting ALK, Ceritinib prevents the proliferation of cancer cells and slows disease progression.

Cerinib is specifically designed for patients with ALK-positive NSCLC, including those who have previously received other ALK inhibitors or are newly diagnosed. The oral capsule formulation allows convenient administration at home, providing a targeted approach to cancer treatment with reduced systemic toxicity compared to traditional chemotherapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Cerinib Capsule 150 mg is indicated for:

• Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

• Patients who are resistant or intolerant to crizotinib or other first-generation ALK inhibitors

• As a monotherapy for targeted inhibition of ALK-driven tumor growth

Its use should be guided by genetic testing to confirm ALK-positive status and administered under the supervision of an oncologist.

Key Benefits

• Targeted therapy for ALK-positive NSCLC, minimizing impact on healthy cells

• Reduces tumor growth by inhibiting the ALK protein, a driver of certain lung cancers

• Oral capsule formulation allows convenient at-home therapy

• Suitable for patients resistant or intolerant to other ALK inhibitors

• Improves progression-free survival in advanced or metastatic ALK-positive NSCLC

• Can be combined with supportive therapies for comprehensive cancer care

Dosage and Administration

Cerinib Capsule 150 mg should be taken exactly as prescribed by an oncologist.

General administration guidelines:

• Standard dose: Typically adjusted based on patient tolerance, liver function, and previous ALK inhibitor exposure

• Take the capsule orally, usually once daily, on an empty stomach or as directed by the physician

• Swallow capsules whole; do not crush, chew, or open them

• Regular liver function tests, ECG monitoring, and clinical follow-up are recommended during therapy

• Adherence to the prescribed schedule is crucial for optimal efficacy

Dosage may be adjusted in patients with hepatic impairment or severe side effects.

Precautions

Before starting Cerinib, inform your doctor if you have:

• Liver disease or elevated liver enzymes

• Heart conditions, particularly QT interval prolongation

• Low blood pressure or electrolyte imbalances

• Pregnancy or breastfeeding (use effective contraception during therapy)

Cerinib should not be combined with medications that can significantly prolong the QT interval unless approved by a physician.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Cerinib is generally well tolerated but may cause side effects, including:

• Gastrointestinal issues: nausea, vomiting, diarrhea, constipation

• Fatigue and headache

• Elevated liver enzymes and possible liver toxicity

• Bradycardia or QT prolongation, requiring monitoring

• Respiratory symptoms, including cough or shortness of breath

Serious side effects may include liver failure, severe cardiac arrhythmias, or severe gastrointestinal toxicity. Immediate medical attention is required if yellowing of the skin/eyes, severe abdominal pain, fainting, or irregular heartbeat occurs.

Storage

Store Cerinib Capsule 150 mg at room temperature below 30°C, in a dry place protected from light. Keep out of reach of children. Do not use after the expiry date.

Cerinib Capsule 150 mg is a targeted ALK inhibitor that provides effective treatment for ALK-positive NSCLC, supporting cancer management with precision therapy under professional supervision.